What is Zenith Epigenetics?
Zenith Epigenetics is a clinical-stage biotechnology firm dedicated to pioneering advanced bromodomain and extra-terminal inhibitors (BETi). The company's core mission is to address significant unmet medical needs in oncology and other disorders by translating complex bromodomain biology into highly effective, targeted therapies. Through strategic collaborations with leading oncology institutions, Zenith is actively developing combination treatment strategies aimed at enhancing therapeutic efficacy and improving patient outcomes. Their primary candidate, ZEN-3694, is currently undergoing clinical evaluation across multiple cancer types, showing promising potential in overcoming established drug resistance mechanisms.
How much funding has Zenith Epigenetics raised?
Zenith Epigenetics has raised a total of $12.3M across 2 funding rounds:
Unspecified
$8M
Private Equity
$4.3M
Unspecified (2014): $8M, investors not publicly disclosed
Private Equity (2014): $4.3M, investors not publicly disclosed
What's next for Zenith Epigenetics?
The substantial enterprise-level backing positions Zenith Epigenetics for accelerated development and potential commercialization of its BET inhibitor pipeline. This strategic investment is expected to fuel further clinical trials, enhance research and development capabilities, and potentially expand the company's therapeutic reach into new indications. The company's focus on combination therapies and its lead candidate, ZEN-3694, suggest a clear trajectory towards addressing complex oncological challenges and solidifying its market position in targeted cancer treatment.
See full Zenith Epigenetics company page
